Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Gemtuzumab Ozogamicin in Relapsed/Refractory AML
NCT04207190Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 12 months. Started Oct 2020; status: completed.
02
Drugs
talazoparib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04207190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207190.